Updated on 17 December 2014
Mr Philippe C Bishop has joined biopharmaceutical company Gilead Sciences
Singapore: Genentech's vice president of oncology unit, Mr Philippe C Bishop, has joined biopharmaceutical company, Gilead Sciences as vice president for hematology and oncology therapeutics.
"Philippe is an accomplished physician with an extensive background in cancer drug development and I am very pleased to welcome him to Gilead," said Mr John McHutchison, executive vice president, clinical research, Gilead Sciences. "Philippe's appointment reflects Gilead's ongoing commitment to further building a leading hematology and oncology therapeutic area. His clinical development expertise, translational focus and strategic leadership will be of great value as we work to advance our growing pipeline of therapies for hematological malignancies and solid tumors."
At Genentech, Dr Bishop was responsible for the development of Avastin, contributed to many of the company's oncology pipeline therapeutics and was a member of the Roche/Genentech joint leadership team. Prior to joining Genentech, Dr Bishop led efforts to develop cancer therapies at Johnson & Johnson and Sanofi-Aventis. Dr Bishop also previously held positions at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH).
"Over the last several years, Gilead has worked to build strong expertise and an extensive pipeline within the hematology and oncology areas," said Dr Bishop. "I am excited to join this dedicated, scientifically focused team, which shares my commitment and passion for scientific innovation, and I look forward to working with them to bring new therapeutic options to people living with cancer."